SCHEMBL27000669

COCCO[C@H]1C(OP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(N)nc3=O)[C@@H](OCCOC)C2OP(=O)(O)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)[C@@H](OCCOC)C2OP(=O)(S)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)CC2OP(=O)(S)OC[C@H]2O[C@@H](n3cc(C)c(=O)[nH]c3=O)CC2OP(=O)(S)OC)[C@@H](COP(=O)(O)OC2[C@@H](COP(=O)(S)OC3[C@@H](CO)O[C@@H](n4cnc5c(N)ncnc54)[C@H]3OCCOC)O[C@@H](n3cc(C)c(N)nc3=O)[C@H]2OCCOC)O[C@H]1n1cc(C)c(N)nc1=O

nearest known ligand 0.54

Predicted protein targets (top 4)

	gene	UniProt	supporting neighbours	confidence
▸	DTYMK	P23919	4/20	0.54

▸	RNASEL	Q05823	7/20	0.47

▸	F2	P00734	1/20	0.46

▸	TERT	O14746	2/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL26488597	0.99	DTYMK (0.53)	DTYMKRNASELF2
SCHEMBL26221005	0.99	DTYMK (0.53)	DTYMKRNASELF2TERT
SCHEMBL26220823	0.99	DTYMK (0.53)	DTYMKRNASELF2TERT
SCHEMBL27000436	0.98	DTYMK (0.52)	DTYMKRNASELF2TERT
SCHEMBL27000634	0.98	DTYMK (0.52)	DTYMKRNASELF2TERT
SCHEMBL26220945	0.98	DTYMK (0.53)	DTYMKRNASELF2
SCHEMBL26220798	0.98	DTYMK (0.53)	DTYMKRNASELF2
SCHEMBL26488821	0.97	F2 (0.51)	DTYMKRNASELF2TERT
SCHEMBL26488554	0.97	F2 (0.51)	DTYMKRNASELF2TERT
SCHEMBL27103963	0.97	F2 (0.51)	DTYMKRNASELF2TERT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11873495-B2	Compounds and methods for reducing LRRK2 expression	IONIS PHARMACEUTICALS, INC. (US)	2024-01-16	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11873495-B2	Compounds and methods for reducing LRRK2 expression	LRRK2, PARK7, SNCA	DTYMK 1078/4885RNASEL 259/4885F2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.